Table 1.
Clinical characteristics of The Cancer Genome Atlas Live Hepatocellular Carcinoma sample training and test groups (n = 343)
|
Covariates
|
Sub type
|
Entire TCGA-LIHC, n (%)
|
Test group, n (%)
|
Training group, n (%)
|
P
value
|
| Age (yr) | ≤ 65 | 216 (62.97) | 103 (60.23) | 113 (65.70) | 0.3493 |
| > 65 | 127 (37.03) | 68 (39.77) | 59 (34.30) | ||
| Gender | Female | 110 (32.07) | 59 (34.50) | 51 (29.65) | 0.3971 |
| Male | 233 (67.93) | 112 (65.50) | 121 (70.35) | ||
| Grade | G1 | 53 (15.45) | 27 (15.79) | 26 (15.12) | 0.3 |
| G2 | 161 (46.94) | 85 (49.71) | 76 (44.19) | ||
| G3 | 112 (32.65) | 54 (31.58) | 58 (33.72) | ||
| G4 | 12 (3.50) | 3 (1.75) | 9 (5.23) | ||
| Unknown | 5 (1.46) | 2 (1.17) | 3 (1.74) | ||
| Stage | Stage I | 161 (46.94) | 81 (47.37) | 80 (46.51) | 0.9079 |
| Stage II | 77 (22.45) | 39 (22.81) | 38 (22.09) | ||
| Stage III | 80 (23.32) | 38 (22.22) | 42 (24.42) | ||
| Stage IV | 3 (0.87) | 2 (1.17) | 1 (0.58) | ||
| Unknown | 22 (6.41) | 11 (6.43) | 11 (6.40) | ||
| T | T1 | 168 (48.98) | 86 (50.29) | 82 (47.67) | 0.5683 |
| T2 | 84 (24.49) | 42 (24.56) | 42 (24.42) | ||
| T3 | 75 (21.87) | 37 (21.64) | 38 (22.09) | ||
| T4 | 13 (3.79) | 4 (2.34) | 9 (5.23) | ||
| Unknown | 3 (0.87) | 2 (1.17) | 1 (0.58) | ||
| M | M0 | 245 (71.43) | 118 (69.01) | 127 (73.84) | 0.9551 |
| M1 | 3 (0.87) | 2 (1.17) | 1 (0.58) | ||
| Unknown | 95 (27.70) | 51 (29.82) | 44 (25.58) | ||
| N | N0 | 239 (69.68) | 111 (64.91) | 128 (74.42) | 0.9081 |
| N1 | 3 (0.87) | 2 (1.17) | 1 (0.58) | ||
| Unknown | 101 (29.45) | 58 (33.92) | 43 (25.00) |
T: Tumor; N: Lymph node; M: Metastasis. The P value is indicated for the chi-square test and Kruskal-Wallis test among the three groups.